Skip to main content

Table 1 Demographic and HIV-related characteristics of 491 participants aged 10–24 years receiving ART across Cape Town, November 2018–March 2019

From: Missed opportunities for NCD multimorbidity prevention in adolescents and youth living with HIV in urban South Africa

  Characteristic N = 491a Median (IQR) or n (%)b
Demographics Age at folder review (years)   20 (14–23)
Male   127 (26%)
HIV-related
HIV management Age at ART initiation (years) 473 (96%) 18 (6–21)
Duration on ART (years) 471 (96%) 3.1 (1.1–8.9)
CD4 count (cells/mm3) 395 (80%) 489 (355 --690)
Viral suppression (< 20 copies/ml) 369 (75%) 256 (69%)
Current ART regimenc First line: ABC 3TC EFV   84 (17%)
TDF FTC EFV   298 (61%)
Second line: ABC 3TC LPV/r   39 (8%)
AZT 3TC LPV/r   29 (6%)
Other regimens   41 (8%)
HIV opportunistic infections 28 (6%)  
  Herpes zoster (shingles)   11 (39%)
Pruritic papular eruption   8 (29%)
Oral thrush   2 (7%)
Oral candida   2 (7%)
Oral hairy leucoplakia   1 (3.6%)
Oesophageal candidiasis   1 (3.6%)
Pneumocystis jirovecii pneumonia   1 (3.6%)
HIV Encephalopathy   1 (3.6%)
Cytomegalovirus disease   1 (3.6%)
ART-related conditionsd 8 (2%)  
  AZT-neutropenia   1 (13%)
D4T-lipodystrophy, lipoatrophy   7 (87%)
  1. aDenominator = 491, unless otherwise indicated in this column; bPercentages may not total 100 due to rounding; cCurrent ART regimens: ABC Abacavir, 3TC lamivudine, EFV efavirenz, TDF tenofovir, FTC emtricitabine, LPV/r lopinavir/ritonavir; dART-related conditions: AZT zidovudine, D4T stavudine